First presentation of clinical data from the sixth DXd antibody drug conjugate from the oncology pipeline of Daiichi Sankyo Early results support continued development of DS-3939, a potential first-in ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS-3939 in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results